PTC Therapeutics, Inc. (PTCT) Stock Analysis
A live, multi-source view of PTC Therapeutics, Inc. (PTCT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd.
Sector: Healthcare · Industry: Biotechnology · United States · 991 employees · ptcbio.com
Key statistics · as of 2026-09-05
As of 2026-09-05, PTC Therapeutics, Inc. (PTCT) had a market capitalization of $5.78B (forward 27.7) and a beta of 0.55; the shares traded in a 52-week range of $56.51 – $90.87 (25.4% over the year).
- Market cap
- $5.78B
- Enterprise value
- $6.57B
- Forward P/E
- 27.7
- EPS (trailing)
- $-0.67
- EPS (forward)
- $2.50
- Payout ratio
- 0.0%
- 52-week range
- $56.51 – $90.87
- 52-week change
- 25.4%
- Beta
- 0.55
- Average volume
- 1.7M
- Shares outstanding
- 83.5M
- Short % of float
- 16.60%
- Profit margin
- -3.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, PTC Therapeutics, Inc. (PTCT) last closed at $67.37 (the last completed close before that scan).
Technicals at the scan: RSI 36 (neutral territory), price -5.0% versus its 20-day average, 20-day versus 50-day average spread -5.4%, MACD histogram -0.22.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of PTCT; corporate insiders filed 0 buys and 12 sells (3 distinct filers, latest disclosure 2026-08-28). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Michael Schmertzler (0B/9S), Mark Elliott Boulding (0B/2S), Matthew B. Klein (0B/1S). Who is trading what
RapidTradeView pick record
PTCT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls PTC Therapeutics, Inc. (PTCT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PTCT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.